DefinitionThis section has been translated automatically.
Anti-CIDAMP antibodies are antibodies that are directed against CIDAMPs (Calreticulin-Induced Damage-Associated Molecular Patterns).
General informationThis section has been translated automatically.
CIDAMPs are molecular patterns that arise in the context of cell damage or stress. They belong to the group of DAMPs (Damage-Associated Molecular Patterns), which are released by damaged or apoptotic cells. DAMPs activate the immune system by alerting immune cells and triggering an inflammatory reaction.
PathophysiologyThis section has been translated automatically.
Function of anti-CIDAMP antibodies: Anti-CIDAMP antibodies are directed against these specific molecular patterns and could be autoimmunologically as well as therapeutically relevant:
- Autoimmune diseases: The organism produces such antibodies to neutralize the DAMP signals, but this can also lead to autoimmune reactions.
- Therapeutic application: In research, anti-CIDAMP antibodies could be used specifically to modulate the excessive inflammatory response in certain diseases, such as autoimmune diseases or chronic inflammation.
LiteratureThis section has been translated automatically.
Christophers E Schröder JM (2022) Evolution of innate defense in human skin. Exp Dermatol 31:304-311.
- Fucikova J et al. (2016).Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res76:1746-1756
- Song, Pu et al.(2024) Membranal Expression of Calreticulin Induced by Unfolded Protein Response in Melanocytes: A Mechanism Underlying Oxidative Stress-Induced Autoimmunity in Vitiligo. Journal of Investigative Dermatology 144: 1622 - 1632.e5
- Wang Y et al. (2019) Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity. Med Sci Monit 25:1017-1023.
- Zhang Y et al. (2014) Oxidative stress-induced calreticulin expression and translocation: new insights into the destruction of melanocytes. J Invest Dermatol 134:183-191.